Shopping Cart
- Remove All
- Your shopping cart is currently empty
KRH102140 is a PHD2 activator that reduces angiogenesis by inhibiting HIF-1alpha, used in cardiovascular disease research.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $330 | In Stock | |
5 mg | $790 | In Stock | |
10 mg | $1,120 | In Stock | |
25 mg | $1,670 | In Stock | |
50 mg | $2,180 | In Stock |
Description | KRH102140 is a PHD2 activator that reduces angiogenesis by inhibiting HIF-1alpha, used in cardiovascular disease research. |
Targets&IC50 | 5-LOX:160 nM |
In vitro | KRH102140 is a PHD2 activator that effectively inhibits HIF-1α in hypoxic human osteosarcoma cells. In addition, KRH102140 reduced mRNA levels of downstream target genes of HIF regulation related to angiogenesis and energy metabolism. [1] KRH102140 inhibited 5-LO activity with an IC50 value of 160 ± 23 nmol/l and inhibited LTB in RBL-1 cells. [2] |
In vivo | Oral administration of KRH102140 (10-100 mg/kg) reduced ear edema, myeloperoxidase activity, and LTB production in a mouse inflammatory model. The oral bioavailability of rats was 66%. [2] |
Alias | KRH 102140 |
Molecular Weight | 373.46 |
Formula | C25H24FNO |
Cas No. | 864769-01-7 |
Smiles | FC=1C=CC=CC1CNC=2C=CC=3OC(C=CC3C2)(C)CCC=4C=CC=CC4 |
Storage | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 100 mg/mL (267.77 mM), Sonication is recommended. ![]() | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.